Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is currently conducting a Phase 2 clinical study titled A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment. The study aims to evaluate the efficacy, safety, and tolerability of Lunsekimig as an add-on therapy for adults with high-risk asthma.
The intervention being tested is Lunsekimig, administered via subcutaneous injection every four weeks. It is designed to improve asthma management in patients who are not eligible for existing biologic treatments. The study also includes a placebo group for comparison.
This interventional study employs a randomized, parallel-group design with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on November 7, 2024, and is currently recruiting participants. The last update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The outcome of this study could significantly impact Sanofi’s stock performance and investor sentiment, especially if Lunsekimig proves to be effective. This development could position Sanofi favorably against competitors in the asthma treatment market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.